{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:55:37Z","timestamp":1790474137767,"version":"4.1.0"},"reference-count":60,"publisher":"Impact Journals, LLC","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,5,30]]},"DOI":"10.18632\/oncotarget.3765","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T02:31:59Z","timestamp":1442284319000},"page":"13757-13771","source":"Crossref","is-referenced-by-count":58,"title":["Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors"],"prefix":"10.18632","volume":"6","author":[{"given":"Joseph J.","family":"Sacco","sequence":"first","affiliation":[{"name":"Cellular & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Kenyani","sequence":"additional","affiliation":[{"name":"Cellular & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohra","family":"Butt","sequence":"additional","affiliation":[{"name":"Cellular & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Carter","sequence":"additional","affiliation":[{"name":"Cellular & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Yi","family":"Chew","sequence":"additional","affiliation":[{"name":"Cellular & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"},{"name":"Current address: Cancer Stem Cell Biology, Agency for Science Technology and Research, Genome Institute of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam P.","family":"Cheeseman","sequence":"additional","affiliation":[{"name":"Cellular & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"},{"name":"Current address: MRC Laboratory of Molecular Biology, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Darling","sequence":"additional","affiliation":[{"name":"Cellular & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Denny","sequence":"additional","affiliation":[{"name":"Cellular & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Urb\u00e9","sequence":"additional","affiliation":[{"name":"Cellular & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Clague","sequence":"additional","affiliation":[{"name":"Cellular & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy M.","family":"Coulson","sequence":"additional","affiliation":[{"name":"Cellular & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,4,24]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Mann","year":"2009","journal-title":"Science"},{"key":"2","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Chabner","year":"2009","journal-title":"J Clin Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00412-013-0441-x","article-title":"Transcription and beyond: the role of mammalian class I lysine deacetylases","volume":"123","author":"Seiser","year":"2014","journal-title":"Chromosoma"},{"key":"4","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1128\/MCB.00494-07","article-title":"Role for histone deacetylase 1 in human tumor cell proliferation","volume":"27","author":"Chiocca","year":"2007","journal-title":"Mol Cell Biol"},{"key":"5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1165\/rcmb.2008-0255OC","article-title":"Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke","volume":"40","author":"Rahman","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"key":"6","first-page":"690848","article-title":"Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2","volume":"2011","author":"Chiocca","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/nar\/gki141","article-title":"Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation","volume":"33","author":"Robson","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ncb1837","article-title":"Chfr is linked to tumour metastasis through the downregulation of HDAC1","volume":"11","author":"Seol","year":"2009","journal-title":"Nat Cell Biol"},{"key":"9","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1093\/emboj\/cdg315","article-title":"The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2","volume":"22","author":"Gottlicher","year":"2003","journal-title":"EMBO J"},{"key":"10","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1101\/gad.170605.111","article-title":"Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2","volume":"25","author":"Zhong","year":"2011","journal-title":"Genes Dev"},{"key":"11","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of SAHA as an anticancer agent","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene"},{"key":"12","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/cancers5030919","article-title":"Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies","volume":"5","author":"Natoli","year":"2013","journal-title":"Cancers"},{"key":"13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4155\/ppa.12.21","article-title":"Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer","volume":"1","author":"Wright","year":"2012","journal-title":"Pharmaceutical patent analyst"},{"key":"14","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1038\/onc.2013.512","article-title":"The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells","volume":"33","author":"Coulson","year":"2014","journal-title":"Oncogene"},{"key":"15","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.4161\/cc.25035","article-title":"The deubiquitylase USP15 stabilizes newly synthesized REST and rescues its expression at mitotic exit","volume":"12","author":"Coulson","year":"2013","journal-title":"Cell Cycle"},{"key":"16","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Hasegawa","year":"2012","journal-title":"Cancer Sci"},{"key":"17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1479-5876-10-179","article-title":"BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs","volume":"10","author":"Friedberg","year":"2012","journal-title":"J Transl Med"},{"key":"18","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Powers","year":"2011","journal-title":"Nat Genet"},{"key":"19","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Powell","year":"2011","journal-title":"Nat Genet"},{"key":"20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.molcel.2014.03.002","article-title":"Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O","volume":"54","author":"Therrien","year":"2014","journal-title":"Mol Cell"},{"key":"21","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkq929","article-title":"COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer","volume":"39","author":"Stratton","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"22","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","article-title":"BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression","volume":"16","author":"Schultz","year":"1998","journal-title":"Oncogene"},{"key":"23","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Zhang","year":"2008","journal-title":"Nature"},{"key":"24","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/ng.956","article-title":"Germline BAP1 mutations and tumor susceptibility","volume":"43","author":"Goldstein","year":"2011","journal-title":"Nat Genet"},{"key":"25","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/ng.910","article-title":"Germline mutations in BAP1 predispose to melanocytic tumors","volume":"43","author":"Pirun","year":"2011","journal-title":"Nat Genet"},{"key":"26","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Bowcock","year":"2010","journal-title":"Science"},{"key":"27","first-page":"17","article-title":"Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma","volume":"44","author":"Zhao","year":"2011","journal-title":"Nat Genet"},{"key":"28","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","article-title":"Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers","volume":"48","author":"Davidorf","year":"2011","journal-title":"J Med Genet"},{"key":"29","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ajhg.2013.04.012","article-title":"Germline BAP1 mutations predispose to renal cell carcinomas","volume":"92","author":"Gyapay","year":"2013","journal-title":"Am J Hum Genet"},{"key":"30","first-page":"116","article-title":"Tumours associated with BAP1 mutations","volume":"45","author":"Scolyer","year":"2013","journal-title":"Pathology"},{"key":"31","doi-asserted-by":"crossref","first-page":"E182","DOI":"10.25011\/cim.v35i4.17146","article-title":"BAP1 is a good prognostic factor in advanced non-small cell lung cancer","volume":"35","author":"Shen","year":"2012","journal-title":"Clin Invest Med"},{"key":"32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s12032-013-0541-8","article-title":"Prognostic significance of BRCA1-associated protein 1 in colorectal cancer","volume":"30","author":"Kang","year":"2013","journal-title":"Med Oncol"},{"key":"33","first-page":"651","article-title":"BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma","volume":"45","author":"Murali","year":"2013","journal-title":"Pathology"},{"key":"34","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.juro.2013.09.041","article-title":"BAP1 Immunohistochemistry Predicts Outcomes in a Multi-Institutional Cohort with Clear Cell Renal Cell Carcinoma","volume":"191","author":"Lotan","year":"2014","journal-title":"J Urol"},{"key":"35","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/cncr.28521","article-title":"Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma","volume":"120","author":"Parker","year":"2014","journal-title":"Cancer"},{"key":"36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12253-013-9677-2","article-title":"BAP1 protein is a progression factor in malignant pleural mesothelioma","volume":"20","author":"Popper","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"37","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/bjc.2014.417","article-title":"Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing","volume":"111","author":"Coupland","year":"2014","journal-title":"Br J Cancer"},{"key":"38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB","volume":"465","author":"Muller","year":"2010","journal-title":"Nature"},{"key":"39","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1128\/MCB.01517-08","article-title":"Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1","volume":"29","author":"Wilson","year":"2009","journal-title":"Mol Cell Biol"},{"key":"40","doi-asserted-by":"crossref","first-page":"34179","DOI":"10.1074\/jbc.M109.046755","article-title":"The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1","volume":"284","author":"Dutta","year":"2009","journal-title":"J Biol Chem"},{"key":"41","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cell.2009.04.042","article-title":"Defining the human deubiquitinating enzyme interaction landscape","volume":"138","author":"Harper","year":"2009","journal-title":"Cell"},{"key":"42","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1126\/science.1221711","article-title":"Loss of the tumor suppressor BAP1 causes myeloid transformation","volume":"337","author":"Katavolos","year":"2012","journal-title":"Science"},{"key":"43","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1038\/emboj.2013.243","article-title":"Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis","volume":"32","author":"Brosch","year":"2013","journal-title":"EMBO J"},{"key":"44","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4161\/cc.10.3.14712","article-title":"Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis","volume":"10","author":"Seiser","year":"2011","journal-title":"Cell Cycle"},{"key":"45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature10098","article-title":"Global quantification of mammalian gene expression control","volume":"473","author":"Selbach","year":"2011","journal-title":"Nature"},{"key":"46","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1097\/JTO.0b013e31829e7ef9","article-title":"Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations","volume":"8","author":"Ladanyi","year":"2013","journal-title":"J Thorac Oncol."},{"key":"47","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30227","article-title":"The pathogenesis of mesothelioma","volume":"29","author":"Testa","year":"2002","journal-title":"Semin Oncol"},{"key":"48","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-14-1328","article-title":"Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma","volume":"74","author":"Rauscher","year":"2014","journal-title":"Cancer Res"},{"key":"49","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/1471-2407-13-371","article-title":"BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma","volume":"13","author":"Harbour","year":"2013","journal-title":"BMC Cancer"},{"key":"50","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"Petel","year":"2014","journal-title":"Clin Cancer Res"},{"key":"51","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1586\/era.09.2","article-title":"Future developments in the management of malignant pleural mesothelioma","volume":"9","author":"Santoro","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"52","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Smith","year":"2005","journal-title":"Nature"},{"key":"53","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Di Noia","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"54","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Olgac","year":"2005","journal-title":"J Clin Oncol"},{"key":"55","doi-asserted-by":"crossref","first-page":"42","DOI":"10.6004\/jnccn.2012.0007","article-title":"Novel therapies in phase II and III trials for malignant pleural mesothelioma","volume":"10","author":"Krug","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"56","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study","volume":"366","author":"Carroll","year":"2005","journal-title":"Lancet"},{"key":"57","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Yang","year":"2009","journal-title":"N Engl J Med"},{"key":"58","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Garrido","year":"2012","journal-title":"Lancet Oncol"},{"key":"59","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1078-0432.CCR-11-0946","article-title":"Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma","volume":"18","author":"Harbour","year":"2012","journal-title":"Clin Cancer Res"},{"key":"60","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-08-1163","article-title":"SCG3 transcript in peripheral blood is a prognostic biomarker for REST-deficient small cell lung cancer","volume":"15","author":"Coulson","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T07:53:08Z","timestamp":1589356388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,24]]},"references-count":60,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2015,5,30]]}},"alternative-id":["3765","25970771"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.3765","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,24]]}}}